Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
A
Amy Jones
Researcher
Also affiliated: University of North Carolina at Chapel Hill (2016–2017); Home Office (2017); Children's National (2018–2020); University of Hertfordshire (2019); Loughborough University (2010); George Washington University (2019–2020); Southwestern Educational Society (2019); Manchester University NHS Foundation Trust (2018); Valley Medical Center (2017); Winthrop Rockefeller Foundation (2025)
Faculty Researcher
6 h-index
28 pubs
212 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Amy Jones's research investigates human papillomavirus (HPV) and its impact on cervical intraepithelial neoplasia (CIN). She has published work on therapeutic vaccines, including a randomized double-blind Phase 2 clinical trial evaluating PepCan or Candida adjuvant for treating CIN2/3. Her work also examines factors influencing medical specialty training intentions, such as changes in training structures. Jones's scholarship metrics include an h-index of 6, with 28 total publications and 208 citations. She has collaborated with Charles M. Quick, David W. Ussery, Michael S. Robeson, and William W. Greenfield, each with two shared publications.
Metrics
- h-index: 6
- Publications: 28
- Citations: 212
Selected Publications
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
Collaboration Network
Top Collaborators
Mayumi Nakagawa
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Teresa Evans
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Hannah Coleman
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Jasmine Crane
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Nadia Darwish
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Haley Kelly
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Yong‐Chen Lu
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Charles M. Quick
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
David W. Ussery
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Michael S. Robeson
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Sumit K. Shah
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Takeo Shibata
Kanazawa Medical University
2 shared publications
In database
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Similar Researchers
Based on overlapping research topics
Teresa Evans
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Keanna Marsh
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Behjatolah Montzavi-Karbassi
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Medical Education
Mindy Wilman
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Tanika Pittman
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Medical Education
Susan Miller
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health Sciences Research and Education
Medical Education